Sanofi's CER Deal with Medco's UBC Could Help ID Potential PGx Drugs in Pipeline
June 29, 2011
Sanofi's CER Deal with Medco's UBC Could Help ID Potential PGx Drugs in Pipeline
UBC's CER capabilities could help Sanofi opportunistically apply pharmacogenomic strategies in drug development and commercialize personalized medicines.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sanofi's Iniparib Fails Phase III Study, but Firm Investigating Benefit by Molecular Subtypes
June 15, 2011 / Pharmacogenomics Reporter - Medco Study to Gauge Whether PGx-Based Plavix Dosing is as Effective as Higher-Priced Effient
October 21, 2009 / Pharmacogenomics Reporter - PMC Urges Stakeholders to Provide Feedback as PCORI Opens Comment Period for Methodology Report
July 25, 2012 / Pharmacogenomics Reporter - Following Merger, Express Scripts May Cut Back Medco's Personalized Medicine Programs
May 9, 2012 / Pharmacogenomics Reporter - Will PCORI's Patient-Centered Comparative Effectiveness Research Track with Personalized Rx?
March 7, 2012 / Pharmacogenomics Reporter